Latest News

STAT Plus: Investors are deeply skeptical of Biogen’s Alzheimer’s claims. They still think it could win approval

“This is basically a game of corporate three-card monte.”

Likening Biogen to a sidewalk confidence game is how one particularly cynical portfolio manager of a biotech hedge fund responded when I asked for his take on Tuesday’s shocking biotech news: Biogen’s decision to resurrect its experimental Alzheimer’s drug aducanumab — and pursue regulatory approval — based on a new and more positive analysis from two large clinical trials previously thought to be negative.

Continue to STAT Plus to read the full story…

Source link

Related posts

The physician's white coat: Iconic and comforting or likely covered in germs?


Injection approach to deliver gene-silencing vector effectively blocks ALS progression


STAT Plus: Pharmalittle: Coronavirus clinical trials are going slower than hoped; opioid lawsuit payouts may be less than expected


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World